Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (231-240 of 290) with videos related to

Pageof 29
Sort By:
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology|May 16, 2020
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusionsAnna Luisa Di Stefano, Alberto Picca, Edouard Saragoussi, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Human Mutation|June 1, 2010
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotypeEric Pasmant, Audrey Sabbagh, Gill Spurlock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent GlioblastomaAhmed Idbaih, Michael Canney, Lisa Belin, et al.
Nature Communications|October 2, 2015
Genome-wide association study identifies multiple susceptibility loci for gliomaBen Kinnersley, Marianne Labussière, Amy Holroyd, et al.
Nature|January 12, 2018
A metabolic function of FGFR3-TACC3 gene fusions in cancerVéronique Frattini, Stefano M Pagnotta, Tala, et al.
Neuro-Oncology|October 31, 2019
Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysisCharlie N Saunders, Alex J Cornish, Ben Kinnersley, et al.
Pageof 29

Showing results (231-240 of 290) with videos related to

Sort By:
Pageof 29
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology|May 16, 2020
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusionsAnna Luisa Di Stefano, Alberto Picca, Edouard Saragoussi, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Human Mutation|June 1, 2010
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotypeEric Pasmant, Audrey Sabbagh, Gill Spurlock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent GlioblastomaAhmed Idbaih, Michael Canney, Lisa Belin, et al.
Nature Communications|October 2, 2015
Genome-wide association study identifies multiple susceptibility loci for gliomaBen Kinnersley, Marianne Labussière, Amy Holroyd, et al.
Nature|January 12, 2018
A metabolic function of FGFR3-TACC3 gene fusions in cancerVéronique Frattini, Stefano M Pagnotta, Tala, et al.
Neuro-Oncology|October 31, 2019
Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysisCharlie N Saunders, Alex J Cornish, Ben Kinnersley, et al.
Pageof 29